Eden Research Share Discussion Threads

[investingisatrickygame] 11/8/2018 13:03

Agreed Super.

The fact that a jury (consumers if you will) arrived at this decision, should heighten the association between agro-chemicals and cancer.

Furthermore, with more like litigation to follow, what company wants a portfolio of @legal risk products when mitigating that risk and improving company image can be supported by biocontrols where such products exist.

Lastly, what corporate officer wants to expose themselves to that personal liability and sleepless nights?!

The industry and company boards could see significant change and quickly as a result of this.

I wonder if Eden and other like companies on others watchlists as discussed at this years AGM by Lykele, might be accelerated in terms of corporate deal activity!

[supersonico] 11/8/2018 12:16

Thanks Investing,
Good video.

Damning and 100% unanimous.

'Q16, Was the conduct of Malice and oppression committed, authorised or ratified by one or more officers, directors or managing agents of Monsanto, acting on behalf of Monsanto?

The answer of the Jury was yes'.

I imagine there are a few officers, directors or managing agents of Monsanto who are going to be having a few sleepless nights as the litigation against them gets under way post appeal.

[investingisatrickygame] 11/8/2018 11:18

Go to 2 minutes 45 seconds to hear the verdict being read

[investingisatrickygame] 11/8/2018 10:51

I think we are agreed.

Eden doesn't have to criticise Monsanto/Bayer, but the 'Natural Solution', its differentiators against conventional, Sustainability etc, etc should make for a good newspaper story that one would hope would get strong traction elsewhere and with bag carriers e.g. industry voices, commentators, activists and more.

[investingisatrickygame] 11/8/2018 09:44

Super,

The Monsanto decision and associated publicity is an interesting one.

One might reasonably assume that by association, buyers of product may tar all agro chemical products with the same brush and consider the potential risks of cancer in using such a product.

Eden and Powerscourt have a true Public Relations opportunity to deliver the 'Natural Solution' story through the press and draw attention to themselves. Equally, Sipcam, Sumi-Agro, et al have the opportunity to piggy back on the same with their business users.

This is not Investor Relations, this is Public Relations and Lykele should add some weight to the value of the PR possibilities with Powerscourt.

It is at least, worth a discussion.

[supersonico] 11/8/2018 00:28

Monsanto to Pay $289.2 Million in Landmark Roundup Lawsuit Verdict.

The claimant in the case, groundskeeper Dewayne Johnson, is among more than 5,000 similar plaintiffs across the US.

Jury found Monsanto acted with malice, oppression and fraud.



August 10, 2018 San Francisco, California – – A San Francisco jury returned a verdict today in the case of a former groundskeeper with terminal cancer against Monsanto Company, ordering the agrochemical giant to pay $39.2 million in compensatory damages and $250 million in punitive damages for failing to warn consumers that exposure to Roundup weed killer causes cancer...…….
…………………………..

[investingisatrickygame] 10/8/2018 14:22

Super,

Alex Bouchon seems mighty impressive and certainly of high value to Bayer.

I'd like to know if Eden personnel have had coffee with him too!

[supersonico] 10/8/2018 13:08

I'd be interested to know if any Eden fellows have had Coffee with this Chap.

Alex Bouchon @Head of Bayer 'Leaps'. #Leapsbybayer

Dr. Axel Bouchon serves as Head of Bayer Life Science Center of Bayer HealthCare AG. Dr. Bouchon has been Head of Global Business Development & Licensing at Bayer HealthCare since April 1, 2015. He has temporarily assumed these duties in addition to his current assignment as Head of the LifeScience Center of Bayer AG. He began his career in industry at Cytos Biotechnology AG in Z ¼rich. In 2002, he transferred to Bayer AG as a laboratory manager at the Pharmaceutical Research Center in Wuppertal. From 2007, he was also active in Mergers & Acquisitions for Bayer HealthCare's Pharmaceuticals Division. In 2010 he moved to Singapore as Head of Pharmaceuticals and was then Country Division Head for the Bayer HealthCare subregion Singapore, Malaysia and Brunei. In 2012, he returned to Germany where he was responsible for Strategic Planning at Bayer HealthCare. Before taking over as Head of the LifeScience Center of Bayer AG effective January 1, 2015, he was Senior Vice President of the U.S. company Moderna Therapeutics, Inc. He also founded, financed and managed various start-up companies focusing on human, animal and plant diseases on the basis of the Moderna technology platform. In 1998, he received his degree in biochemistry, organic chemistry and immunology “ with a diploma thesis that he wrote at the German Cancer Research Center â “ from Eberhard Karls University in Tübingen / Germany. He earned his doctorate (Dr. rer. nat.) from Tübingen in 2002 with a thesis that he executed at the Basel Institute for Immunology of Roche AG.

[supersonico] 10/8/2018 12:38

Investing,

Just replace Ginkgo BioWorks with TT and the appropriate Tech blurb below and you have 'one mighty RNS'.

Bayer formed a new company with Ginkgo Bioworks works. Interesting the background of the interim CEO. Just sayin.

Bayer and Ginkgo Bioworks join forces for sustainable agriculture, forming new company with USD 100 million Series

The novel company will focus on transformational beneficial microbes for plants to provide growers with next generation solutions to their biggest challenges / Initial activities will focus on nitrogen fixation, minimizing agriculture’s environmental impact / The work combines the synthetic biology leadership of Ginkgo Bioworks with Bayer’s deep knowledge and experience in agriculture and microbial products



Dr. Mike Miille will be named interim CEO of the new company. He is a biotech veteran in the field of agricultural use of the microbiome, former CEO of AgraQuest and currently Vice President Strategy and Business Management Biologics at Crop Science, a division of Bayer. The Board of Directors of the new company will be composed of two representatives from Ginkgo Bioworks - Dr. Jason Kelly and Dr. Reshma Shetty - and two representatives from Bayer - Dr. Axel Bouchon and Dr. Juergen Eckhardt.

[investingisatrickygame] 10/8/2018 10:13

Super,

One way or another, Eden needs to get the TT monkey of its back. Hopefully to the positive, deal done and profitable from day one with no revenue delays.

I do admire your persistence of your theme. As I said before, to bring this altogether in one mighty RNS is a big ask. I think it is more likely that Eden would get taken out at the same time rather than manage a much bigger workload with such a small team. How could they manage all of that as they are!

The repetition of promise is becoming a bit tiresome as an investor with zero return so far. Its not that we do not understand the communicated regulatory process; it is moreso that Eden has also communicated that deals, named ones, are going live by X date.

Time to deliver those, communicate their true value when done, make sure the share price behaves accordingly and then go back to NPD. Too many patents with too little value reflected is where we sit right now. Nothing can mask that reality and I bet that is exactly how institutional investors view Eden.

[supersonico] 10/8/2018 09:38

Morning Northwick,

It's also interesting how a certain character on the MW site who gives the impression of having special cosy insights always shares his little teases kindly during Eden news droughts, delivering encouraging , motivating and timely snippets to a weary team.

Little 'on message' pats on the head and sweets for all the wide eyed children, routinely papering over Eden's habitual incongruence , seamlessly managing our expectations over the horizon into another six months, year after year.

[northwick] 10/8/2018 08:24

Gm SuperHope You haven't lost sleep over Eden? it ain't worth it. Take care

[supersonico] 09/8/2018 15:06

Northwick,

The CEO I think/hope is likely doing his level best under strict NDA's ..also I'm confident we will see some of the fruits of the ground work that he has done 'in the coming months'.

[northwick] 09/8/2018 14:24

Could Eden do well with a new CEO and a communications director .This CEO has failed to deliver value for its shareholders for last 4 years.

[investingisatrickygame] 09/8/2018 14:21

50p will likely see a very large churn in the shareholder base. In reality I think that is needed to freshen things up and start the next part of the journey.

[northwick] 09/8/2018 14:13

Kind of you reply so soon, Super.I hope you are proven right, and hope we see 25p sometime this year. Any higher would be a bonus and a blessing for many of the long term shareholders. Regards

[supersonico] 09/8/2018 13:56

Hi Northwick,

The radio Bayer/TT silence so far means my theory could be playing out. Once they make an announcement it may well fall apart. But it could also be confirmed.

I am confident and feel.. odd as it may sound, more confident as the dual delays continue as in my delusional mind the longer the parallel delays go on for the stronger my thesis becomes ..to me at least.

I think were in for a big announcement and I suppose that's what keeps me unflustered and relatively happy.

I may well be completely wrong but I do feel Eden's prospects are good and think share price @ 50-100p by 2020/21 is achievable even without my fantasy TT/ Bayer hook up . VRS style.

[northwick] 09/8/2018 13:40

SuperDespite the failures and delays you seem to be unflustered and are happy to wait for ever more. have I misinterpreted your sentiments?

[supersonico] 09/8/2018 13:29

42 days since 'Short Order' and the four plus years of obviously unsynchronised parallel TT and Bayer delays remain..

..Delayed in Parallel and obviously unsynchronised.

[supersonico] 09/8/2018 13:18

Who's Owning Cedroz, Sean ?



Application Development & Technical Service Manager, Crop Protection
Kingsport, TN, US
Research and Development
Aug 9, 2018
……………………………………..


supersonico - 25 Jun 2018 - 12:15:31 - 4124 of 4344
Eden Research - EDEN
Eastman ..Cedroz..

This Post has been advertised and Reposted for 3 months.
Is anyone Owning the technical development of nematicide in the US.
Perhaps it needs more than One owner?



Application Development & Technical Service Manager, Crop Protection
Apply now
Date: Jun 12, 2018
Location: Kingsport, TN, US

The Responsibilities for the AD&TS, Crop Protection role are the following:
• Support the technical development of Eastman's plant growth regulator in US
• Own the technical development of nematicide in the US.

[woolybanana] 09/8/2018 12:00

Was the Mavelone rep there too?